MAPK6 and cancer: Targeting ERK3 in cancer could involve the inhibition of its kinase domain, thereby modulating the phosphorylation of downstream effectors, and/or the C‐terminal region containing the C34 domain and the FHIEDE motif, thereby interfering with protein–protein interactions.